Placebo | | | | |
Body weight (kg) | 1.9 (5.0) | −3.9 (10.1) | NS | NA |
BSA (m2) | 0.02 (0.06) | −0.07 (0.1) | NS | NA |
SBP (mm Hg) | −4.4 (2.1) | −6.6 (2.8) | <0.05 | NA |
DBP (mm Hg) | −5.8 (2.0) | −8.7 (2.8) | <0.01 | NA |
Pulse pressure (mm Hg) | 2.4 (2.6) | 1.95 (3.4) | NS | NA |
LV mass index (g/m2) | −2.9 (2.9) | −10.2 (4.1) | NS | NA |
Ascending AoDist (cm2/dyn×10–6) | −0.6 (0.4) | −0.06 (0.7) | NS | NA |
Abdominal AoDist (cm2/dyn×10–6) | −0.4 (0.3) | 0.01 (0.7) | NS | NA |
Pulse wave velocity (m/s) | 0.7 (0.4) | 0.66 (0.6) | NS | NA |
Glipizide | | | | |
Body weight (kg) | 4.8 (5.7) | 5.3 (6.4) | NS | NS |
BSA (m2) | −0.03 (0.02) | 0.01 (0.02) | NS | NS |
SBP (mm Hg) | −4 (5.7) | −8.7 (6.5) | NS | NS |
DBP (mm Hg) | 1.8 (3.4) | −5.9 (3.9) | NS | NS |
Pulse pressure (mm Hg) | −4.5 (3.2) | −0.6 (5.7) | NS | NS |
LV mass index (g/m2) | 1.9 (8.1) | −12.0 (9.2) | NS | NS |
Ascending AoDist (cm2/dyn×10–6) | −0.5 (0.3) | −0.65 (0.3) | NS | NS |
Abdominal AoDist (cm2/dyn×10–6) | 0.5 (0.2) | 0.1 (0.2) | NS | NS |
Pulse wave velocity (m/s) | 0.4 (0.6) | 2.8 (0.7) | 0.012 | <0.05 |
Metformin | | | | |
Body weight (kg) | 1.2 (2.7) | 2.2 (3.4) | NS | NS |
BSA (m2) | 0.01 (0.02) | −0.06 (0.03) | NS | NS |
SBP (mm Hg) | −7.0 (2.1) | −3.7 (4.4) | 0.03 | NS |
DBP (mm Hg) | −4.8 (2.0) | −10.5 (4.3) | 0.03 | NS |
Pulse pressure (mm Hg) | −1.1 (3.1) | 7.0 (5.7) | NS | NS |
LV mass index (g/m2) | −8.1 (3.4) | −16.8 (7.0) | 0.03 | NS |
Ascending AoDist (cm2/dyn×10–6) | −0.04 (0.3) | −0.3 (0.5) | NS | NS |
Abdominal AoDist (cm2/dyn×10–6) | 0.1 (0.3) | −0.65 (0.4) | NS | NS |
Pulse wave velocity (m/s) | −0.3 (0.4) | 2.2 (0.7) | 0.01 | <0.05 |